Cited 6 times in
Cumulative Incidence of Hepatocellular Carcinoma and Hepatitis B Surface Antigen Seroclearance After Nucleos(t) Ide Analogue-Induced Hepatitis B E Antigen Seroclearance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이관식 | - |
dc.contributor.author | 이정일 | - |
dc.contributor.author | 이현웅 | - |
dc.date.accessioned | 2020-06-17T00:52:38Z | - |
dc.date.available | 2020-06-17T00:52:38Z | - |
dc.date.issued | 2020-04 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/176165 | - |
dc.description.abstract | Background: Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear. We investigated the cumulative incidence of hepatocellular carcinoma (HCC) and evaluated hepatitis B surface antigen (HBsAg) seroclearance in patients undergoing nucleos(t) ide analogue (NA)-induced HBeAg seroclearance. Methods: In this retrospective cohort study, 203 patients with CHB were HBsAg and HBeAg seropositive before NA (entecavir or tenofovir) treatment. All patient who experienced NA -induced HBeAg seroclearance were recruited. Patients with documented HBeAg seroclearance were followed-up every 6 months. Baseline characteristics and laboratory results were recorded. Results: The mean age at HBeAg seroclearance was 40 years (range, 20-84), and the mean follow-up duration was 5 years (range, 2-11). The cumulative incidence of HCC was 1.5 to 11.5% at 1 to 8 years after HBeAg seroclearance. Cirrhosis was the only significant factor for HCC development (hazard ratio [HR], 24.651; confidence interval [CI], 3.018 to 201.365; P = 0.003). The cumulative incidence of HBsAg seroclearance was 3.5 to 18.7% after 1 to 8 years from HBeAg seroclearance. Conclusions: A significant proportion of patients developed HCC after NA-induced HBeAg seroclearance. The presence of liver cirrhosis at the time of HBeAg seroclearance serves as an independent factor for HCC development. Some patients with NA-induced HBeAg seroclearance achieved HBsAg seroclearance. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC GASTROENTEROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Cumulative Incidence of Hepatocellular Carcinoma and Hepatitis B Surface Antigen Seroclearance After Nucleos(t) Ide Analogue-Induced Hepatitis B E Antigen Seroclearance | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hyun Woong Lee | - |
dc.contributor.googleauthor | Jung Il Lee | - |
dc.contributor.googleauthor | Saein Kim | - |
dc.contributor.googleauthor | Sora Kim | - |
dc.contributor.googleauthor | Hye Young Chang | - |
dc.contributor.googleauthor | Kwan Sik Lee | - |
dc.identifier.doi | 10.1186/s12876-020-01236-9 | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A03122 | - |
dc.contributor.localId | A03292 | - |
dc.relation.journalcode | J00356 | - |
dc.identifier.eissn | 1471-230X | - |
dc.identifier.pmid | 32305059 | - |
dc.subject.keyword | Hepatitis B e antigen seroclearance | - |
dc.subject.keyword | Hepatitis B s antigen seroclearance | - |
dc.subject.keyword | Hepatitis B virus | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.contributor.alternativeName | Lee, Kwan Sik | - |
dc.contributor.affiliatedAuthor | 이관식 | - |
dc.contributor.affiliatedAuthor | 이정일 | - |
dc.contributor.affiliatedAuthor | 이현웅 | - |
dc.citation.volume | 20 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | e113 | - |
dc.identifier.bibliographicCitation | BMC GASTROENTEROLOGY, Vol.20(1) : e113, 2020-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.